Pharmaceutical company Mallinckrodt has introduced a prefilled, single-dose injector designed to simplify the administration of Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. Approved by the US Food and Drug Administration earlier this year, the Acthar Gel SelfJect injector offers a more convenient alternative to the traditional multidose vial and syringe method, with enhanced safety features including a hidden needle to prevent needlestick injuries.

Available in 2 dosage strengths (40 USP units/0.5 and 80 USP units/1.0 mL), SelfJect is intended for subcutaneous administration in adults and is designed to ensure accurate dosing while reducing preparation steps. The new device aims to improve treatment adherence, particularly for patients with dexterity issues, according to Dr. Kostas Botsoglou of the Rheumatology Center of Western New York.